Kitov Pharma Ltd (KTOV) Stock News
NASDAQ:KTOV - Nasdaq -
KTOV Latest News, Press Relases and Analysis
H.C. Wainwright Thinks Kitov Pharmceuticals’ Stock is Going to Recover
38 Stocks Moving in Friday's Pre-Market Session
Gainers Socket Mobile, Inc. (NASDAQ: SCKT) rose 65.8% to $2.42 in pre-market trading after the company reported a rise in earnings for the third quarter. Ever-Glory...
33 Stocks Moving in Tuesday's Pre-Market Session
Gainers Aptorum Group Limited (NASDAQ: APM) shares rose 883.6% to $12.00 in pre-market trading after the company announced the launch of an infectious disease liquid biopsy...
Dosing underway in Kitov Pharma's NT219 study in advanced cancer patients (NASDAQ:KTOV)
Kitov Pharma (NASDAQ:KTOV) announces that the first patient has been dosed in the Phase 1/2 clinical trial evaluating NT219 as monotherapy treatment of advanced solid tumors, as well as in combination with cetuximab, for the treatment of recurrent and/or metastatic solid tumors and head and neck cancer or colorectal adenocarcinoma.
Kitov Pharma receives new patents for CM24 and NT219 in China (NASDAQ:KTOV)
Kitov Pharma (NASDAQ:KTOV) announces receipt of notification from the Chinese Patent Office to grant two separate patents for its lead oncology candidates CM24, a monoclonal antibody targeting CEACAM1, and NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.
PDD, GAN among premarket losers
Gevo (NASDAQ:GEVO) -26% on launch of direct offering; pared down overnight gains after Trafigura deal.GAN (NASDAQ:GAN) -16% on Q2 earnings.Xcel Brands (NASDAQ:XELB) -10%.Pinduoduo (NASDAQ:PDD) -9% on Q2 earnings.Kitov Pharma (NASDAQ:KTOV) -7%.AirNet Technology (NASDAQ:ANTE) -7%.OpGen (NASDAQ:OPGN) -6%.MICT (NASDAQ:MICT) -6%.Top Ships (NASDAQ:TOPS) -5%.iFresh (NASDAQ:IFMK) -6%.Sypris Solutions (NASDAQ:SYPR) -6%.Allied Esports Entertainment (NASDAQ:AESE) -5%.Blink Charging (NASDAQ:BLNK) -5%.AngloGold Ashanti (NYSE:AU) -5% after being told by South African Gov.
Kitov Pharma announces ADS ratio change (NASDAQ:KTOV)
Kitov Pharma (NASDAQ:KTOV) has changed the ratio of its ADSs to ordinary shares from 1 ADS representing 1 ordinary shares to a new ratio of 1 ADS representing 10 ordinary shares.The ratio change will be effective at the beginning of trading on August 21.For ADS holders, the ratio change will have the same effect as a 1/10 reverse ADS split.The ADS ratio change was to enable the Company to regain its compliance as per Nasdaq listing rule.
Is Kitov Pharmaceuticals Holdings (KTOV) Outperforming Other Medical Stocks This Year?
Is (KTOV) Outperforming Other Medical Stocks This Year?
Are These Penny Stocks To Buy Or Avoid Before The Weekend?
Penny Stocks To Watch Before The End Of The Week
3 Penny Stocks To Buy Under $1.50 Right Now, But For How Long?
Penny Stocks That Can Be Bought For Less Than $1.50 Right Now
Is Kitov Pharmaceuticals Holdings (KTOV) Outperforming Other Medical Stocks This Year?
Is (KTOV) Outperforming Other Medical Stocks This Year?
Kitov Pharma launches early-stage study of NT219 in solid tumors (NASDAQ:KTOV)
Kitov Pharma (KTOV -6.8%) initiates Phase 1/2 trial of NT219 as monotherapy for advanced solid tumors, as well as in combination with cetuximab, a monoclonal antibody that blocks epithelial growth factor receptor, as a second-line or third-line treatment of recurrent and metastatic squamous cell carcinoma of the Head & Neck CancerSmall molecule NT219 is a dual inhibitor targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.The primary objectives of the trial are to evaluate safety, pharmacokinetics, identify the recommended dose, and establish preliminary efficacy of NT219.Preliminary data from the first part of the study should be available in H2 2021.
Kitov Pharma launches mid-stage study of NT219 in solid tumors (NASDAQ:KTOV)
Kitov Pharma (KTOV -6.8%) initiates Phase 1/2 trial of NT219 as monotherapy for advanced solid tumors, as well as in combination with cetuximab, a monoclonal antibody that blocks epithelial growth factor receptor, as a second-line or third-line treatment of recurrent and metastatic squamous cell carcinoma of the Head & Neck CancerSmall molecule NT219 is a dual inhibitor targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.The primary objectives of the trial are to evaluate safety, assess pharmacokinetics, identify the recommended dose, and establish preliminary efficacy of NT219.The company expects to report preliminary data from the first part of the study in second half of 2021.
3 Biotech Penny Stocks To Buy Or Hold According To Analysts
Penny Stocks Analysts Are Bullish On In Biotech
Kitov Pharma +18% on new European patent for anti-CEACAM1 antibody (NASDAQ:KTOV)
The European Patent Office intends to grant a new patent to Kitov Pharma (NASDAQ:KTOV) for application entitled “Humanized antibodies against CEACAM1.”The patent covers protein and DNA sequences pertaining to humanized antibodies capable of specific binding to human CEACAM1 molecules, including monoclonal antibody, CM24, pharmaceutical compositions comprising these antibodies, as well as methods for their use in treating and diagnosing cancer and other conditions.Shares are up 18% premarket.
Kitov Pharma's strong cash balance (NASDAQ:KTOV)
As of June 2020, Kitov Pharma (KTOV +7.8%) reported +$60M in cash which it plans to use for conducting the two clinical studies to be initiated in 2020. The cash is likely to support company's activit
T2 Biosystems among healthcare gainers; Inovio Pharmaceuticals leads the losers
Gainers: Alterity Therapeutics (NASDAQ:ATHE) +66%. Qualigen Therapeutics (NASDAQ:QLGN) +37%. T2 Biosystems (NASDAQ:TTOO) +37%. Akero Therapeutics (NASDAQ:AKRO) +28%. AxoGen (NASDAQ:AXGN) +24%.Losers: